TO Approved for public release, distribution unlimited

Similar documents
TO Approved for public release, distribution unlimited

TO Approved for public release, distribution unlimited

TO Approved for public release, distribution unlimited

SUSCEPTIBILITY OF SUCKLING MICE TO VARIOLA VIRUS

TO Approved for public release, distribution unlimited

Yellow Fever Vaccine: Direct Challenge of Monkeys Given Graded Doses of 17D

TO Approved for public release, distribution unlimited

TO Approved for public release, distribution unlimited

TO Approved for public release, distribution unlimited

UNCLASS8 n-fd \AD DOCUMENTATION, CENTER 11DEFENSE FOR SCIENTIFIC AND TECHNICAL INFORMATION / ~CAMERON STATION, ALEXANDRIA.

111 II1 I 111 III ? 0 9, AD-A CT 31i931 ANNUAL REPORT D TIC RDMUNDO KRAISELBURD S AUGUST 28, 1991.

TO Approved for public release, distribution unlimited

TO Approved for public release, distribution unlimited

FACTORS INFLUENCING VARIOLA VIRUS GROWTH ON THE CHORIOALLANTOIC MEMBRANE OF EMBRYONATED EGGS

C for 2 hr at 22,620 X G. The supernatant fluid. was discarded and the sediment resuspended to

Effect of Vaccine, Route, and Schedule on Antibody

INTRABULBAR INOCULATION OF JAPANESE ENCEPHALITIS VIRUS TO MICE

TO Approved for public release, distribution unlimited

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TO Approved for public release, distribution unlimited

Studies on Japanese B Encephalitis Virus Vaccines from Tissue Culture

15 s p ing iold. vtransiation. DDC AVAIAILIy XTCE. DEPARMNT OF THE ARMY Fort Detrick Frederick,, "frland. Repducd by the

(From the Department of Epidemiology and Virus Laboratory, School of Pubbic Health, University of Michigan, Ann Arbor) Methods

Report Documentation Page

SEROLOGIC EVIDENCE OF INFECTION OF WHITE-TAILED DEER IN TEXAS WITH THREE CALIFORNIA GROUP ARBOVIRUSES, (JAMESTOWN CANYON, SAN ANGELO, AND KEYSTONE)

IMMUNITY OF MICE FOLLOWING SUBCUTANEOUS VACCINATION WITH ST. LOUIS ENCEPHALITIS VIRUS

te AND TECHNOLOGY CENTER

N. A STUDY OF THE VIRULENCE OF THE BRUCELLA VACCINE STRAIN

(From the Laboratories of The Rockefeller Institute for Medical Research*)

Teclin ical information Agency

(From the Laboratories of the International Health Division of The Rockefeller Foundation, New York)

A SEROLOGICAL SURVEY OF ARBOVIRAL DISEASES AMONG THE HUMAN POPULATION OF THE ANDAMAN AND NICOBAR ISLANDS, INDIA

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

TO Approved for public release, distribution unlimited

TO Approved for public release, distribution unlimited

Dengue Infection at Children's Hospital of Bangkok

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

Leukocytes and Interferon in the Host Response to Viral Infections

J07 Titer dynamics, complement fixation test and neutralization tests

Enzo Paoletti, Ph.D. Albany State Health Laboratory Albany, NY 12201

INACTIVATION OF VENEZUELAN

ULTRAFILTRATION OF RECENTLY ISOLATED NEUROTROPIC VIRUSES

What is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection?

Enhancing the Immunogenicity of a Tetravalent Dengue DNA Vaccine

Enteric Immunization with Live Adenovirus Type 21 Vaccine

UNCLASSIFIED AD DEFENSE DOCUMENTATION CENTER FOR SCIENTIFIC AND TECHNICAL INFORMATION CAMERON STATION. ALEXANDRIA, VIRGINIA UNCLASSIFIED

(From the Division of Laboratories and Research, New York State Department of Healtk~ Albany)

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

Chikungunya Virus Vaccine Prepared by

THE ANTIBODY RESPONSE OF GUINEA PIGS TO EPIDEMIC TYPHUS

UNCLASSIFIED. o ADm/e ARMED SERVICES TECHNICAL INFORMATION AGENCY ARLINGTON HALL STATION ARLINGTON 12, VIRGINIA UNCLASSIFIED

Clinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY

AFRL-RH-WP-TR

4 2OO&O0 1/3 L030ý. STINFO Copy EFFECT OF MONOMETHYLHYDRAZINE ON GLUCOSE LEVELS IN RATS AMRL-TR JULY 1976

Dengue-2 Vaccine: Viremia and Immune Responses in Rhesus Monkeys

TO Approved for public release, distribution unlimited

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited

D TIC 89 7" C:' ' 14. SJULO i99 June CSAFETY 0HEPATITIS ELECTE. Supported by U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND

inoculated to give an initial viable count of approximately 104 to 105 cells per ml, and incubated at 37 C with shaking, or under the desired gas

Roles of microrna-mediated Drug Resistance in Tumor Stem Cells of Small Cell Lung Carcinoma

IMMUNIZATION OF GUINEA PIGS AGAINST LYMPHO- CYTIC CHORIOMENINGITIS WITH FORMOLIZED TISSUE VACCINES

TO Approved for public release, unlimited

Interferon Induction with Statolon in the Intact Animal'

1111 L L 1I M 0. MlCROL'OF1. R[ Si0 t ItN TI SI CH ART NATIQNA,

INFLUENCE OF INGESTED FOODS ON THE ORAL TOXICITY IN MICE OF

THE CYTOPATHOGENIC ACTION OF BLUETONGUE VIRUS ON TISSUE CULTURES AND ITS APPLICATION TO THE DETECTION OF ANTIBODIES IN THE SERUM OF SHEEP.

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

TO Approved for public release, distribution unlimited

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

(From the Department of Animal and Plant Pathology of The Rockefeller Institute for Medical Research, Princeton, New Jersey)

(From the Biological Department, Chemical Corps, Camp Derrick, Frederick, Maryland)

PEDV Research Updates 2013

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

Pathogenesis of Simian Foamy Virus Infection in Natural and Experimental Hosts

Immune System. Name: Class: Date: Multiple Choice Identify the choice that best completes the statement or answers the question.

Experiment #1 TARGET Mouse Model Group. Report prepared by Paul Converse, Ph.D. and Eric Nuermberger, M.D. March 1, 2006

Diagnosis of California La Crosse Virus Infection by Counterimmunoelectrophoresis

PEDV Research Updates 2013

[333] STUDIES IN NEWCASTLE DISEASE IV. RAPID METHODS OF DIAGNOSIS. purposes. in the field. In both instances the methods described have proven

TO Approved for public release, distribution unlimited

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

TO Approved for public release, distribution unlimited

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

value as a medium for the in vivo cultivation of different

Antiviral Activity of 10-Carboxymethyl-9-Acridanone

OCCURRENCE OF POLIOMYELITIS VIRUS IN AUTOPSIES, PATIENTS, AND CONTACTS*

I.NCLASSIFIED. Reproduced by DOCUMENT SERVICE CENTER KNOTT BUILDING, DAYTON, 2, OHIO

CLINICAL RELEVANCE. D. A. Grosenbaugh, DVM, PhD a C. S. Backus, DVM, PhD b K. Karaca, DVM, PhD a J. M. Minke, DVM, PhD c R. M. Nordgren, DVM, PhD a

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

UNCLASSIFIED AD "DFFNSE DOCUMENTATION CENTER FOR SCIENTIFIC AND TECHNICAL INF;ORMATION CAMERON STATION, AIEXANDHIA. VIRGINIA UNCLASSHFIED

Avian Infectious Bronchitis Vaccine, Inactivated

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

Transcription:

UNCLASSIFIED AD NUMBER AD449729 NEW LIMITATION CHANGE TO Approved for public release, distribution unlimited FROM Distribution authorized to U.S. Gov't. agencies and their contractors; Administrative/Operational Use; Aug 1964. Other requests shall be referred to Army Biological Labs., Fort Detrick, MD 21701. AUTHORITY ABL d/a ltr, 27 Sep 1971 THIS PAGE IS UNCLASSIFIED

UNCLASSI"]FI[ED AD449729 DEFENSE DOCUMENTATION CENTER SCIENTIFIC FOR AND TECHNICAL INFORMATION CAMERON STATION A!EXANDRIA, VIRGINIA UNCLASSIFIED

NOTICE: When government or other drawings, specifications or other data &re used for any purpose other the in connection with a deinitely related goverment procurment operation, the U. S. Government thereby incursl no responsibility, nor any obligation whatsoever, and tha fact that the Governmment my have formalatea, furnished, or in any way supplied the said drawings, apeifi.eations, or other data Is not to be regarded by implication or othervise as in any manner licensing the holder or any other person or corporation, or conveying any rights or pdrmision to manufacture, use or sell amy patented invention that may in any way be related thereto.

TECHNIAL MANUSCRIPT 159 O.,.4*... itcrossprotection MECHANISM BETWEEN SINDBIS AND SEMLIKI FOREST VIRUSES IN MICE....ffli.. AUGUST 1964...... l D D C DDC-IRA Ir UNITED STATES ARMY BIOLOGICAL LABORATORIES FORT DETRICK

13. S. AR<MY BIOLOGICAL LABORA'fORTES Fort Detrick, Frederick, Maryland TECHNICAL MANUSCRIPT 159 CROSS-HPROTEOTION MECHANISM BETWEEN SIDBIS AND SEMLIKI FOREST VIR~USES IN MICE Orville M. Brand W41118m P. Allen Virus and. Rickettsa Division 21~ DIRECTOR OF BIOLOGICAL RESEARCH Project 1.A01250J.BD2801 August 1964

This publication or any portion thte6f may not be reproduced vithout specific authorization from the Commnding Officer, U. S. Army Biological Laboratories, ATTN: Technical Releases Branch, Technical Information Division, Fort Detrick, Frederick, Maryland. 21.701. However, DDC is authorized to reproduce the publication for U. S. Government purposes. The information in this publication has not been cleared for release to the public. DDC n~fo IV~A~Z( Qualified requeators may obtain copies of this publication directly from DIX], Foreign announdement and diaiina'6ion of this publioation by DDC is limited,

3 PBSTRACT The mode of action and site for cross-protection among Group A arboviruses has been studied in mice using Sindbis and Semliki Forest (SF) viruses as a working model. Swiss mice immunized with Sindbis virus by the intracerebral route demonstrated substantial resistance to intraparitoneal challenge with lethal doses of SF virus. Serologic examination by hemagglutination-inhibition, complement fixation, and neutralization revealed that antibody to SF virus first appeared iri the serum of Sindbis-immune and normal mice four days after challenge. SF antibody attained maximum titers in Sindbis-vaccinated mice 10 days after challenge with SF virus and slowly declined thereafter. Antibody responses to SF virus in normal mice paralleled responses found in Sindbis-mmune mice, but all normal mice succumbed to SF infection seven days after challenge. Periodic titration of the blood, brain, liver, and spleen in 10- to l-gram mice showed a detectable quantity of SF virus in the organs of both groups 24 hours after challenge. Maximum titers of SF virus appeared in the blood, liver, and spleen by the.thdrd day after challenge. Mean virus titers in the brain increased progressively in both groups of mice from the first through tne seventh day, tho last day.of assay; on the seventh day, however, the titer of SF virus in the brains of Sindbis-immune mice was two to three logs less than that in the brains of normal mice. The results imply (a) that an anamnestic response of circulating antibody to SF virus could not be demonstrated and thus could not account for cross-protection observed in mice immunized with Sindbis virus, and (b) that the brain appears to be the site for possible localized cross-production resulting from previous experience with a related virus.

5 CROSS -PROTECTION MECIIkNISM BEIWEEN SINDBIS AND SE4LIKT FOREST VIRUSES IN MICE Cross-protection among arboviruses has been demonstrated by numerous investigators; however, certain aspects of these immunological overlaps are not understood and require further elucidation. Past experience in this laboratory has shown Sindbis and Semliki Forest (SF) viruses to be acceptable models for further studies of variables encountered in cross-protection. In adult mice Sindbis virus elicits antibodies that do not cross react with Semliki virus antigen by hemagglutination-inhibition or neutralization; also, mice inmunized with Sindbis virus demonstrate substantial resistance to intraperitoneal (IP) challenges with Semliki virus. Experiments were designed to determine (a) if there was an anamnestic response from antibodies that were not detectable in serum prior to challenge, and (b) location and length of -time that challenge virus remained in the Sindbis-immune and normal hosts. Swiss mice* (10 to 14 gram) were immunized by intracerebral (IC) inoculation with lo SND0 of Sindbis virus. Twenty-eight days after im munization equal numbers of Sindbis-mfune and normal mice were challenged TP witho.1 ml of a lo- dilution of Semliki Forest virus seed. Ten of the challenged mice were picked at specified intervals and exsanguinated. The blood was collected in three pools, each containing the blood of three to four mice. Each serum pool was assayed by hemagglutination-inhibition (HI), complement fixation (CF) and neutralization (NT) procedures. The HI and CF tests were performed in micro-plates against eigbt units of antigen using serological techniques similar to those described by Clarke and Casals.** NT tests were conducted in suckling mice using the constant virus-serum dilution technique. The NT titer'was defined as that dilution of serum capable of protecting 50 per cent of the assay mice against 150 suckling mouse intraperitoneal LD 5 0 of SF virus. The SF virus dilution used for the challenge was also titrated in Sindbis-immune and normal mice at the time of challenge. Table I shows the per cent of mice in the titration that succumbed to SF virus. The greatest resistance within the Sindbis-vaccinated group occurred among mice inoculated with the 10-3 dilution of SF virus seed. Progressively less resistance Vas observed among immunized mice that received higher dilutions of SF virus. This decrease of resistance as the challenge dose decreases is eomewhat * In conducting the research reported herein, the investigators adhered to "Principles of Laborat6ry Animal Care" as established by the National Society for Medical Research. ** Clarke, D.H., and Casals, J. "Techniques of hemagglutination and hemagglutination-inhibition with arboviruses," Am. J. Trop.Aed. Hyg. 7:561-573, 1958.

TABLE 1. TTTRATION OP c1hallenge Dyo"L OFp cf4ili.t ORET ViTJs TN 8STNDPTF,3-iMMNE AND NORMAL. MIE Diluton o SOFPer Cent of Deaths in Mice Virus Inoculated S Icb Isa-.hImne.. Normal.Co ntrol 30 80 10-4 70 l 30 20.0-8 2.0 D a. Challenge dilutionl of Semliki Forest virus. characteristic of this heterotypic challenge system. The normal mie exhibited the expected. end point with an LDOO titer of 5.6 log, A comparison of HI, CF and. NT results are shown in Figure 1 for sera of mice challenged. with a heterotypic virus. Attention is first directed to data obtained from tests with Sindbia antigen (Figure 1 a). L Exartnation of the Siridhio-immune serum against Oindbis antigen (nfgare I a) showr. a continued. Increase in antibody titer through Day 4F, particularly for the N.J. and NT reactions; however, by the sixth day the Sindbis-immune mice experienced a -two- to four-fold. loss and recovery In. Siridbis antibody. Max..mum antibody titers appear In 8 to ID days with a gradual drop in IfI and NT reactions by Day 23. Again, all three test procedures appear -to agree on the general course of antibody response. In Stidb.i-Immure mice, SF antibody (Figure 1 b) could *be demonctrated on Day )Iby all three ass~ay procedures; a maximum antibody iater was attained beiveen 8 and 1( days. All threc procedures elorie~ly agree on the course of antibody rise.

57 0 (A - C4 m C') -00* 1: C44 Z-L- C= - ~LV) 0 0

The 8F antibody response in nonimmunized was similar to that found in Sindbis-immune mice. The HT, CF and NT titers each appeared by Day 4 and increased through Day 6; after the seventh day all normal mice succumbed to SF virus. From the data just examined, cross-protection was shown to be present in Sindbls-immune mice challenged with SP virus. No significant differences could be demonstrated between the rates of antibody formation to SF virus in normal and Sindbis-immunized mice, and it is concluded that the anamnestic response hypothesized for antibody to SF virus was not in evidence to account for the demonstrated cross-protection. In a second experiment, Sindbis-immune and normal control mice were challenged IP with 103.5 LD5o of Semliki Forest virus 28 days after immunization. Six mice were picked at random from each group and sacrificed at one hour, six hours, and one, two, three, five, and seven days after challenge. The blood, brain, liver and spleen were aseptically removed, and the individual organs were prepared as a 10 per cent suspension in brain-heart infusion broth. Each tissue suspension was titrated in 10- to 14-gram mice by-the IC route to determine the LDgo of. each sample. The data obtained from assay of the individual organs and blood are recorded on Tables II, III, and IV and show the range of virus titers per six mice and the geometric mean per period of assay. In Table II the viremias of Sindbis-immune and normal mice appear almost identical. Each group of mice demonstrated the presence of SF virus by Day 1 and a maximum virus titer by Day 2. SF titers diminished considerably from Day 3 through Day 7; however, some virus was still present in the immunized mice on Day 7. Titration of liver suspensions showed essentially the same virus response as described for 'the blood, and since virus titers in the liver were usually lower than -titers in the blood, it is probable that virus found in the liver was a reflection of the virus present in the blood in this organ. As shown in Table II, SF virus was demonstrable in the spleens of Sindbis--immune mice 24 hours after challenge and reached a maximum titer by Day 2. For reasons not yet understood, titration samples taken on Day 5 proved to be toxic for mice and this toxicity prohibited a valid measurement of the virus. Some SF virus was still present in spleen samples on the seventh day after challenge.

9 TABLE fl. VIRUS TITRS IN MOUSE BLOOD AFTER INTBAPERITONFAL TNOCULATTON OF SETMLIKI FOREST VIRUS Sindbis Immune Normal Control Tim of... Sacrifice Range Mean j Range Mean I Hr. 0 b 0 0 0 6 Hr. 0 0 0 0 1 Day 0-3.5 <1.0 0-3.7 1.1 2 Days 0-3.9 2.7 0-6.5 2.8 3 Days 0-4.5 2.0 0-4.5 1.9 5 Days 0-3.0 <1.0 0-1.4 1.0 7 N7ix 0-i.5 <1.0 0 a. Geometric mean of titers of tissues from 6 mice. b. Titers represent log MD 50 oof virus per 0.03 ml of tissue. "0" titer means no virus was detectable in 0.03 ml of a 10 per cent suspension of tissue, the lowest dilution tested, SF virus was present in the spleens of normal mice six hours after challenge; however, more distinct virus titers appeared by Day 1 and continued to increase through Day 3. Day 5 samples showed a decline in virus titer and did not appear to be toxic for assay mice. Again, some virus was present in the few remaining normal mice of Day 7. The concentration of SF virus in the spleens of Sindbis-immune mice was frequently higher than those in blood or liver samples. This suggested that the spleen was probably a site of viral multiplication during the early phases of the infection. A comparison of the virus titers obtained in blood, liver and spleen showed considerable decline in virus multiplication after Day 3. In the previous experiment SF neutralizing antibody was shown to be present in immune and control groups of mice by Day 4 and could probably account for reduction in SF virus titers in the blood and viscera beyond Day 3.

1.0 TABIE I[iI VIOUS TIT1,.. IN MOUSE SP.,WEE1N AFi.:hi< NTIPI'i:dUTOlEIA, INOCUTATION OF SEIIKI,'OREBT VIRUS Sindbis Immune Normal Control Time of Sacrifice Range Mean - / Range Mean 1Th0, 0 0 0 6 Hrs. 0 0 0-2.2 < 1.0 1 Day 0-3.7 1.2 0-<1.5 < 1.0 2 Days 0-4,5 3,2 0-5.5 2.7 3 Days o-4.2 2.7 2.5-4.6 3.7 5 Days 0-5.0 < 1.0 0-2.8 1.2 7 Days ()-3.1 ]. 0-1.0.10 a. Geometric mean of titers of tissues from 6 mice. b. Titers represent log ID 0 of virus per 0.03 ml of tissue. "b" titer means no virus was detectable in 0.03 ml of a 10 per cent suspension of tissue, the lowest dilution tested. As in the other tissues examined, virus appeared in the brsins of both groups of mice by Day 1 (Table IV). The average increase of virus In the brains of Sindbis-immune mice paralleled virus multiplication shown for normal control mice through Day 3 and may be an artifact caused by viremic blood in the brain. Unlike that in other tissues examined, virus tjters In the brain continued 'to increase from Day 3 to Day 7, the last day of assay. Although virus multiplication was still In progress in the brains o. r Sindbis-immune mice, a two- to three-log difference could be discerned between immune and nonimmune groups on Day 7. This can beat be shown by Figure 2, which graphically demonstrates the suppression of virus multi - plication in the immunized group and the unrestricted viral replication in normal mice. Dissemination of virus is believed to be in:itiated soon after

TABLE!V. VIRUS TITERS IN MOUSE BRAINS AFIER 11TTRAPERITONEAL INOCULATION OF SEMLIKI FOREST VIRUS Sindbis Immune Normal Control Time of_ Sacrifice Range Mean2 / Range Mean 1 Hr. o - I / 0 0 0 6 frs. 0 0 0 <1.0 1 Day 2,4 <I.0 0-1.0 <1.0 2 Days 1.0-3.2 1,8 0-4.5 1.8 3 Days 0-4.3 2,2 0-4.0 2.3 5 Days 0-6,5 3.3 0-6.3 5.0 7 Days 0.6.6 3.8 6.1-6.8 6.3 a. Geometric mean of titers of tissues from 6 mice, b. Titers represent log LD60 of virus per 0,03 ml of tissue. "0" titer means no virus was detectable in 0.03 ml of a 10 per cent suspension of tissue, the lowest dilution tested, intraperitoneal challenge end is probably carried via the peripheral circulation to liver, spleen and possibly the brain. The brain shown a continued increase in Virus biter end Is considered the "target" organ for viral infection. From the data just examined, the blood and liver are only remotely involved In viral multiplication. Spleen samples ahow some evidence of increased viral replication; however, this is probably stifled by the appearonce of neutralizing antibody on Dny ht. Hence, the most prominent site of viral reproduction Is the brain.

12 x0 Un 0) X o-,*i PEW Ln M C os(]l U-O ol

'3 Difference observed :[I.i SF brain titers (Figure 2) beot;'elnu :n.ndbls-- immune and nonimmune mice appear to he the result of a lo lzed resistance from previous experience with a related virus in the braio. The nature of this localized resistance is presently unknown; however, it night be speculated that the initial immunization sensitizes the tissues of the cen.- tral nervous system in such a way that they suppress the multiplication of related viruses either by a localized production of antibody or by a refractory state of cell susceptibility.